
Bayer Launches Phase I Trial of Actinium-225 Therapy for Liver Cancer
Bayer Launches Phase I Trial of Actinium-225 Therapy for Liver Cancer Bayer has announced the initiation of a Phase I clinical trial for BAY 3547926 (225Ac-GPC3), an investigational targeted alpha radiopharmaceutical designed to treat advanced hepatocellular carcinoma (HCC) by targeting…